title: Antitumor and immunomodulatory effects of recombinant fusion protein rMBP-NAP through TLR-2 dependent mechanism in tumor bearing mice.
abstract: The pro-inflammatory and immunomodulatory properties of Helicobacter pylori neutrophil activating protein (Hp-NAP) not only make it to play an important role in disease pathogenesis but also make it to be a potential candidate for therapeutic applications, including vaccine and drug development. Our previous work demonstrated that the recombinant Hp-NAP fused with the maltose binding protein of Escherichia coli (rMBP-NAP) play an important role in regulating the differentiation of Th1 cells. In this study, we investigated the ability of rMBP-NAP to induce antitumor immunity using two murine models of hepatoma H22 and sarcoma S180. Subcutaneous administration of mice with rMBP-NAP resulted in an about 40%-50% decrease of tumor growth compared with that of the control mice. Splenocytes from the tumor-bearing mice treated with rMBP-NAP showed a significant accumulation of CD4(+) IFN-γ-secreting cells, which is a cytokine profile of Th1 cells. Furthermore, intravenous injection of T2.5, toll like receptor (TLR) 2 blocking antibody, significantly recede the antitumor effect of rMBP-NAP and the production of IFN-γ induced by rMBP-NAP. Our findings indicate that potentiality of rMBP-NAP to be a candidate for the development of immunomodulatory antitumoral drugs.
authors.affiliation: School of Life Sciences, Zhengzhou University, 100 Science Road, Zhengzhou 450001, PR China. Electronic address: tingwang@zzu.edu.cn.
authors.forename: Ting
authors.initials: T
authors.lastname: Wang
authors.affiliation: School of Life Sciences, Zhengzhou University, 100 Science Road, Zhengzhou 450001, PR China. Electronic address: rame12360325@vip.qq.com.
authors.forename: Xilong
authors.initials: X
authors.lastname: Liu
authors.affiliation: Henan Academy of Medical and Pharmaceutical Sciences, Zhengzhou University, 40 University Road, Zhengzhou 450052, PR China. Electronic address: jizhenyu@zzu.edu.cn.
authors.forename: Zhenyu
authors.initials: Z
authors.lastname: Ji
authors.affiliation: School of Life Sciences, Zhengzhou University, 100 Science Road, Zhengzhou 450001, PR China. Electronic address: menyingli@126.com.
authors.forename: Yingli
authors.initials: Y
authors.lastname: Men
authors.affiliation: School of Life Sciences, Zhengzhou University, 100 Science Road, Zhengzhou 450001, PR China. Electronic address: 13838226521@163.com.
authors.forename: Mingxuan
authors.initials: M
authors.lastname: Du
authors.affiliation: School of Life Sciences, Zhengzhou University, 100 Science Road, Zhengzhou 450001, PR China. Electronic address: dingcong158@126.com.
authors.forename: Cong
authors.initials: C
authors.lastname: Ding
authors.affiliation: School of Life Sciences, Zhengzhou University, 100 Science Road, Zhengzhou 450001, PR China. Electronic address: wuyahong1618@163.com.
authors.forename: Yahong
authors.initials: Y
authors.lastname: Wu
authors.affiliation: School of Life Sciences, Zhengzhou University, 100 Science Road, Zhengzhou 450001, PR China. Electronic address: Liux@zzu.edu.cn.
authors.forename: Xin
authors.initials: X
authors.lastname: Liu
authors.affiliation: School of Life Sciences, Zhengzhou University, 100 Science Road, Zhengzhou 450001, PR China. Electronic address: qzkang@zzu.edu.cn.
authors.forename: Qiaozhen
authors.initials: Q
authors.lastname: Kang
mesh_terms: D000818:Animals; D001426:Bacterial Proteins / Q000494:pharmacology* / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000494:pharmacology* / Q000627:therapeutic use; D002454:Cell Differentiation / Q000187:drug effects; D004926:Escherichia coli / Q000378:metabolism; D005260:Female; D007155:Immunologic Factors / Q000494:pharmacology* / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods*; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000473:pathology; D011993:Recombinant Fusion Proteins / Q000494:pharmacology / Q000627:therapeutic use; D012510:Sarcoma 180 / Q000188:drug therapy / Q000276:immunology; D013154:Spleen / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D018417:Th1 Cells / Q000187:drug effects; D051195:Toll-Like Receptor 2 / Q000187:drug effects*
chemical_list: D001426:Bacterial Proteins; D019496:Cancer Vaccines; D007155:Immunologic Factors; D011993:Recombinant Fusion Proteins; C493486:Tlr2 protein, mouse; D051195:Toll-Like Receptor 2; C092412:neutrophil-activating protein A, Helicobacter pylori
keywords: Antitumor immunotherapy; TLR2; Th1 immune response; immunomudulatory drug; rMBP-NAP